{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:02:01Z","timestamp":1784970121652,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,25]]},"DOI":"10.7759\/cureus.113340","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:50:22Z","timestamp":1784969422000},"source":"Crossref","is-referenced-by-count":0,"title":["Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Mimicking Central Nervous System Infection in an Adolescent: A Case Report"],"prefix":"10.7759","author":[{"given":"Panhui","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell B","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, et al.. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023, 22:268-82. 10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier R","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, et al.. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021, 20:762-72. 10.1016\/S1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi E","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ, et al.. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022, 13:885218. 10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius S","year":"2020","unstructured":"Jarius S, Lechner C, Wendel EM, et al.. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients. J Neuroinflammation. 2020, 17:262. 10.1186\/s12974-020-01825-1","journal-title":"J Neuroinflammation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.722404","article-title":"Clinical and imaging features of patients with encephalitic symptoms and myelin oligodendrocyte glycoprotein antibodies","volume":"12","author":"Wang J","year":"2021","unstructured":"Wang J, Qiu Z, Li D, et al.. Clinical and imaging features of patients with encephalitic symptoms and myelin oligodendrocyte glycoprotein antibodies. Front Immunol. 2021, 12:722404. 10.3389\/fimmu.2021.722404","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209303","article-title":"Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease","volume":"102","author":"Cacciaguerra L","year":"2024","unstructured":"Cacciaguerra L, Abdel-Mannan O, Champsas D, et al.. Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease. Neurology. 2024, 102:e209303. 10.1212\/WNL.0000000000209303","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing","volume":"78","author":"Sechi E","year":"2021","unstructured":"Sechi E, Buciuc M, Pittock SJ, et al.. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol. 2021, 78:741-6. 10.1001\/jamaneurol.2021.0912","journal-title":"JAMA Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325121","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","volume":"92","author":"Banks SA","year":"2021","unstructured":"Banks SA, Morris PP, Chen JJ, et al.. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. 2021, 92:384-90. 10.1136\/jnnp-2020-325121","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317267","article-title":"Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review","volume":"105","author":"Vosoughi AR","year":"2021","unstructured":"Vosoughi AR, Ling J, Tam KT, Blackwood J, Micieli JA. Ophthalmic manifestations of myelin oligodendrocyte glycoprotein-IgG-associated disorder other than optic neuritis: a systematic review. Br J Ophthalmol. 2021, 105:1591-8. 10.1136\/bjophthalmol-2020-317267","journal-title":"Br J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters P","year":"2020","unstructured":"Waters P, Fadda G, Woodhall M, et al.. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. 2020, 77:82-93. 10.1001\/jamaneurol.2019.2940","journal-title":"JAMA Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.25259\/JCIS_49_2020","article-title":"An anatomic, imaging, and clinical review of the medial longitudinal fasciculus","volume":"10","author":"Fiester P","year":"2020","unstructured":"Fiester P, Baig SA, Patel J, Rao D. An anatomic, imaging, and clinical review of the medial longitudinal fasciculus. J Clin Imaging Sci. 2020, 10:83. 10.25259\/JCIS_49_2020","journal-title":"J Clin Imaging Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2023.301","article-title":"Myelin oligodendrocyte glycoprotein-related isolated internuclear ophthalmoplegia mimicking multiple sclerosis","volume":"51","author":"Handzic A","year":"2024","unstructured":"Handzic A, Margolin E. Myelin oligodendrocyte glycoprotein-related isolated internuclear ophthalmoplegia mimicking multiple sclerosis. Can J Neurol Sci. 2024, 51:717-8. 10.1017\/cjn.2023.301","journal-title":"Can J Neurol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002024","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as bilateral internuclear ophthalmoplegia: a case report","volume":"44","author":"Park JS","year":"2024","unstructured":"Park JS, Lee HJ, Chun BY. Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as bilateral internuclear ophthalmoplegia: a case report. J Neuroophthalmol. 2024, 44:e578-80. 10.1097\/WNO.0000000000002024","journal-title":"J Neuroophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52001","article-title":"Peripheral nervous system manifestations of MOG antibody associated disease","volume":"11","author":"Gupta P","year":"2024","unstructured":"Gupta P, Paul P, Redenbaugh V, et al.. Peripheral nervous system manifestations of MOG antibody associated disease. Ann Clin Transl Neurol. 2024, 11:1046-52. 10.1002\/acn3.52001","journal-title":"Ann Clin Transl Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02751","article-title":"Pathogenesis and treatment of neurologic diseases associated with Mycoplasma pneumoniae infection","volume":"9","author":"D'Alonzo R","year":"2018","unstructured":"D'Alonzo R, Mencaroni E, Di Genova L, Laino D, Principi N, Esposito S. Pathogenesis and treatment of neurologic diseases associated with Mycoplasma pneumoniae infection. Front Microbiol. 2018, 9:2751. 10.3389\/fmicb.2018.02751","journal-title":"Front Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52162","article-title":"Matched oligoclonal bands: diagnostic utility and clinical characteristics","volume":"11","author":"Hoshina Y","year":"2024","unstructured":"Hoshina Y, Abbatemarco JR, Rodenbeck SJ, et al.. Matched oligoclonal bands: diagnostic utility and clinical characteristics. Ann Clin Transl Neurol. 2024, 11:2846-54. 10.1002\/acn3.52162","journal-title":"Ann Clin Transl Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. Paediatric MOG Consortium Consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens AL","year":"2020","unstructured":"Bruijstens AL, Wendel EM, Lechner C, et al.. E.U. Paediatric MOG Consortium Consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol. 2020, 29:41-53. 10.1016\/j.ejpn.2020.10.005","journal-title":"Eur J Paediatr Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577812","article-title":"Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis","volume":"364","author":"Nepal G","year":"2022","unstructured":"Nepal G, Kharel S, Coghlan MA, Rayamajhi P, Ojha R. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): a systematic review and meta-analysis. J Neuroimmunol. 2022, 364:577812. 10.1016\/j.jneuroim.2022.577812","journal-title":"J Neuroimmunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516152-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mimicking-central-nervous-system-infection-in-an-adolescent-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T08:50:23Z","timestamp":1784969423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516152-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mimicking-central-nervous-system-infection-in-an-adolescent-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.113340","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}